Sparkle: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?

HIGHLIGHTS

• who: Kato Rans from the Department of Radiation Oncology, University Hospitals Leuven, Herestraat have published the research: SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?, in the Journal: (JOURNAL) of April/28,/2022
• what: Approximately 36% of patients included in this trial had low-volume metastatic disease . Hormonal therapy Premature discontinuation of trial treatment Participants may voluntary withdraw their consent to participate in the Trial for any reason at any time.
• how: The androgen receptor inhibitor . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.